A novel method for office aspiration curettage in cases of retained products of conception: A randomized controlled trial

Meir Pomeranz, Nitzan Goren Gepstein, Michal Ovadia, Zvi Klein, Yair Daykan, Ron Schonman, Nissim Arbib, Meir Pomeranz, Nitzan Goren Gepstein, Michal Ovadia, Zvi Klein, Yair Daykan, Ron Schonman, Nissim Arbib

Abstract

Introduction: Missed abortion can be treated with medication or aspiration curettage. A Karman aspiration cannula is another option. We evaluated its success in evacuating retained products of conception (RPOC) based on symptoms, endometrial thickness, endometrial irregularity, and blood flow seen on Doppler ultrasound (indicative of placenta).

Material and methods: This prospective, randomized, nonblinded trial was conducted in a university-affiliated medical center. It included 40 women diagnosed with missed abortion and two failed courses of 600 µg buccal misoprostol, one week apart, randomly assigned to treatment or controls. One week after the second misoprostol course, immediately after evaluating endometrial thickness, endometrial irregularity using Doppler ultrasound, and with blood flow indicative of RPOC, women in the aspiration group underwent endometrial suction with a Karman aspiration cannula. The 5-6 mm cannula attached to a 60 mL syringe was inserted into the uterus under ultrasound guidance. The contents were aspirated until the uterus was empty. Control group patients did not receive additional treatment. All were scheduled for ambulatory, operative hysteroscopy under anesthesia 1 month later (departmental protocol). On that day, all women with RPOC on Doppler ultrasound underwent hysteroscopy. Bleeding days, days with pain, pain according to visual analog scale, length of hospitalization, and infection rate were recorded. NIH clinical trial registration number NCT02917785.

Results: In the study group, 90% did not need hysteroscopy, compared with 50% of controls (p = 0.014). No complications were noted. At all visits, we used Doppler ultrasound to exclude or confirm RPOC. Pathology revealed RPOC in all women who underwent aspiration. Average visual analog scale score for office aspiration (n = 20) was 4.9 ± 3.6. vs. 6.3 ± 3.4 for the first (p = 0.157) and 4.7 ± 3.3 for the second (p = 0.836) misoprostol treatment cycle. The treatment group experienced 6.1 days of bleeding and the control group experienced 1.4 days (p = .006).

Conclusions: Based on our criteria of diagnosing RPOC according to symptoms, endometrial thickness, endometrial irregularity, and blood flow indicative of placental tissue seen on Doppler ultrasound and histo-pathological confirmation, aspiration using Karman cannula can be an effective therapeutic approach. It may be a safe alternative for women with RPOC after misoprostol failure.

Keywords: aspiration; hysteroscopy; misoprostol; missed abortion; retained products of conception.

© 2021 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).

References

REFERENCES

    1. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Gynecology. ACOG Practice bulletin no. 200: early pregnancy loss. Obstet Gynecol. 2018;132:e197-207.
    1. Neilson JP, Gyte GM, Hickey M, Vazquez JC, Dou L. Medical treatments for incomplete miscarriage. Cochrane Database Syst Rev. 2013;(3):CD007223.
    1. Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynecol Obstet. 2007;99:S160-S167.
    1. Paul ME, Mitchell CM, Rogers AJ, Fox MC, Lackie EG. Early surgical abortion: efficacy and safety. Am J Obstet Gynecol. 2002;187:407-411.
    1. Machtinger R, Seidman DS, Goldenberg M, Stockheim D, Schiff E, Shulman A. Transvaginal ultrasound and operative hysteroscopy in women undergoing medical termination of pregnancy as a part of routine follow-up. Fertil Steril. 2005;84:1536-1538.
    1. Asherman JG. Amenorrhoea Traumatica (Atretica). BJOG. 1948;55:23-30.
    1. Hooker AB, Aydin H, Brolmann HAM, Huirne J, Huirne JAF. Long-term complications and reproductive outcome following medical and surgical management of retained products of conception: a systematic review. Fertil Steril. 2016;105:156-164.
    1. Goldenberg M, Schiff E, Achiron R, Lipitz S, Mashiach S. Managing residual trophoblastic tissue: Hysteroscopy for directing curettage. J Reprod Med. 1997;42:26-28.
    1. Vitale SG, Parry JP, Carugno J, et al. Surgical and reproductive outcomes after hysteroscopic removal of retained products of conception: a systematic review and meta-analysis. J Minim Invasive Gynecol. 2021;28:204-217.
    1. Smorgick N, Barel O, Fuchs N, Ben-Ami I, Pansky M, Vaknin Z. Hysteroscopic management of retained products of conception: meta-analysis and literature review. Eur J Obstet Gynecol Reprod Biol. 2014;173:19-22.
    1. Karman H, Potts M. Very early abortion using syringe as vacuum source. Lancet. 1972;1:1051-1052.
    1. Deans R, Abbott J. Review of intrauterine adhesions. J Minim Invasive Gynecol. 2010;17:559-569.
    1. Linnakaari R, Helle N, Mentula M, et al. Trends in the incidence, rate and treatment of miscarriage - Nationwide register-study in Finland, 1998-2016. Hum Reprod. 2019;7(34):2120-2128.
    1. Wu HL, Marwah S, Wang P, Wang QM, Chen XW. Misoprostol for medical treatment of missed abortion: a systematic review and network meta-analysis. Sci Rep. 2017;7:1664.
    1. Graziosi GCM, Mol BWJ, Reuwer PJH, Drogtrop A, Bruinse HW. Misoprostol versus curettage in women with early pregnancy failure after initial expectant management: a randomized trial. Hum Reprod. 2004;19:1894-1899.
    1. Schreiber CA, Creinin MD, Atrio J, Sonalkar S, Ratcliffe SJ, Barnhart KT. Mifepristone pretreatment for the medical management of early pregnancy loss. N Engl J Med. 2018;378:2161-2170.
    1. Kovavisarach E, Jamnansiri C. Intravaginal misoprostol 600 μg and 800 μg for the treatment of early pregnancy failure. Int J Gynecol Obstet. 2005;90:208-212.
    1. Srikhao N, Tannirandorn Y. A comparison of vaginal misoprostol 800 microg versus 400 microg for anembryonic pregnancy: a randomized comparative trial. J Med Assoc Thai. 2005;88:S41-47.
    1. Zhang J, Gilles JM, Barnhart K, Creinin MD, Westhoff C, Frederick MM. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med. 2005;353:761-769.
    1. Jakopič Maček K, Blaganje M, Kenda Šuster N, Drusany Starič K, Kobal B. Office hysteroscopy in removing retained products of conception-a highly successful approach with minimal complications. J Obstet Gynaecol. 2019;40:1122-1129.
    1. Davis A, Westhoff C, De Nonno L. Bleeding patterns after early abortion with mifepristone and misoprostol or manual vacuum aspiration. J Am Med Womens Assoc. 1972;2000(55):141-144.
    1. Niinimäki M, Jouppila P, Martikainen H, Talvensaari-Mattila A. A randomized study comparing efficacy and patient satisfaction in medical or surgical treatment of miscarriage. Fertil Steril. 2006;86:367-372.

Source: PubMed

3
구독하다